Le Lézard
Classified in: Health
Subjects: TDS, WOM, FVT

binx health To Present At The Canaccord Genuity Medical Technology And Diagnostics Forum


BOSTON, Nov. 19, 2019 /PRNewswire/ -- binx health, the pioneer in anywhere, anytime testing for women's health, today announced that Jeffrey Luber, president and CEO is scheduled to present on Thursday, November 21, 2019 at 11:00 a.m. ET at the Canaccord Genuity Medical Technology & Diagnostics Forum in New York City.

binx health is the pioneer in anywhere care for consumers where they live, work and shop. binx develops proprietary, rapid desktop PCR instruments and mobile solutions for at home, physician-ordered testing to bring consumers from "worry-to-well" quickly and effectively. For more visit www.mybinxhealth.com (PRNewsfoto/binx health)

Management will be available for one-on-one meetings throughout the conference. The presentation will be webcast live and may be accessed by visiting https://mybinxhealth.com/category/news/ on the News section of the company's website.

ABOUT BINX HEALTH
binx health is the pioneer in anywhere care in women's health for consumers where they live, work and shop. With the first FDA 510(k) cleared solution for the rapid testing of Chlamydia (CT) and Gonorrhea (NG) in women, binx is poised to transform care for the two most tested for sexually-transmitted infections globally. Today, 40% of patients who test positive for CT/NG do not come back for treatment once they leave a physician's office?making the need for rapid test and treat solutions paramount. We also expand access to testing through mobile solutions for at-home, physician-ordered testing that aim to bring consumers from "worry-to-well" in the palm of their hands, for those unwilling or unable to get tested in-clinic. Starting with sexually-transmitted infections, we aim to reverse trends of rising infections among young people wherever they are, and move into broader family health through the expansion of our point-of-care and at-home menus. binx health's investors include financial investors Johnson & Johnson Innovation, Novartis Venture Fund, LSP, BB Biotech, RMI Investments and Technology Venture Partners and strategic investors Consort Medical (whose wholly owned subsidiary Bespak is the manufacturer of the company's low-cost, proprietary multiplex cartridges) and China-based Wondfo Biotech.

SOURCE binx health


These press releases may also interest you

at 09:25
CartiHeal, developer of the proprietary Agilitm-C implant for the treatment of joint surface lesions in traumatic and osteoarthritic joints, has secured an additional $15 million equity investment from Bioventus, a global leader in orthobiologics....

at 09:23
The global Advanced Sterilization Products market is forecast to reach USD 13.06 billion by 2027, according to a new report by Reports and Data. The global market for sterilization is increasing considerably from the increasing implementation of...

at 09:17
Listening to recorded classical music is a non-invasive method to improve quality of life for a person living with heart failure, according to a recent study published in the Journal of Cardiac Failure, and accompanied by editorials from...

at 09:15
Alternative Medical Enterprises, LLC has been awarded patents for the United States and European Union for its Medical Cannabis Encapsulation Technology and Trademark on EnCapstm. EnCaps Products are an expanding products line at the 23 MÜVtm Medical...

at 09:14
Verified Market Research recently published a report, "Telehealth Market by Component (Software & Services, Hardware), by Application (Teleradiology, Tele-consultation, Tele-ICU, Tele-stroke, Tele-psychiatry), by End-User (Providers, Patients,...

at 09:10
Elligo Health Research®, a healthcare-enabling research organization, is launching their fully realized System of Accelerated Research (SOAR) model for decentralized (DCTs) and hybrid trial models with fully remote monitoring capabilities. Only...



News published on 19 november 2019 at 08:30 and distributed by: